Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

INTRODUCTION: Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard of care for patients with NSCLC with acquired EGFR T790M mutations. We assessed changes in serial plasma cell-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Bin-Chi, Hsu, Wei-Hsun, Lee, Jih-Hsiang, Yang, Ching-Yao, Tsai, Tzu-Hsiu, Liao, Wei-Yu, Ho, Chao-Chi, Lin, Chia-Chi, Shih, Jin-Yuan, Yu, Chong-Jen, Soo, Ross A., Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474212/
https://www.ncbi.nlm.nih.gov/pubmed/34589970
http://dx.doi.org/10.1016/j.jtocrr.2020.100099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474212/
https://www.ncbi.nlm.nih.gov/pubmed/34589970
http://dx.doi.org/10.1016/j.jtocrr.2020.100099

Ejemplares similares